Dechra Pharmaceuticals PLC Director/PDMR Shareholding (1418D)
24 April 2017 - 9:30PM
UK Regulatory
TIDMDPH
RNS Number : 1418D
Dechra Pharmaceuticals PLC
24 April 2017
24 April 2017
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
In accordance with article 19(1) of the Market Abuse
Regulations, the Company was notified today that due to a change in
personal circumstances Ian Page's total beneficial interest in the
Company is now 811,308 shares, which represents 0.871% of the
current issued share capital.
The reduction in his beneficial shareholding relates to shares
held by his sons, Andrew, David and Michael Page, who are no longer
classified as a connected person under the Market Abuse
Regulations.
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the EU Market Abuse
Regulation.
Notification of Dealing Form
1. Details of the Person Discharging Managerial
Responsibility ("PDMR")/person closely
associated with them ("PCA")
--- --------------------------------------------------------------
a) Name Ian Page
--- ----------------------------- -------------------------------
2. Reason for the notification
--- --------------------------------------------------------------
a) Position/status Director
--- ----------------------------- -------------------------------
b) Initial notification/ Initial Notification
amendment
--- ----------------------------- -------------------------------
3. Details of the Issuer
--- --------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
--- ----------------------------- -------------------------------
b) LEI code N/A
--- ----------------------------- -------------------------------
4. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- --------------------------------------------------------------
a) Description Ordinary Shares of 1 pence
of the financial each
instrument
Identification ISIN: GB0009633180
code
--- ----------------------------- -------------------------------
b) Nature of Shares held by sons, who are
the transaction no longer connected people
--- ----------------------------- -------------------------------
c) Price(s) and Price(s) Volume(s)
volumes(s)
Nil cost 2,600
Nil cost 2,000
Nil cost 2,000
--- ----------------------------- --------------- --------------
d) Aggregated
information
* Aggregate volume 6,600
Nil cost
* Price
--- ----------------------------- -------------------------------
e) Date of the 2017.04.24
transaction
--- ----------------------------- -------------------------------
f) Place of the Outside a trading venue
transaction
--- ----------------------------- -------------------------------
For further information, please contact:
Suzana Cross, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals
and related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHOKQDBDBKDCQB
(END) Dow Jones Newswires
April 24, 2017 07:30 ET (11:30 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024